OXiGENE is conducting multiple clinical trials in oncology. To learn about enrollment criteria and who to contact for further information about each trial, please click on the links provided. If you think that you meet the criteria shown, please contact the appropriate study coordinator for further information. Other than by participating in a clinical trial, patients cannot receive ZYBRESTAT (fosbretabulin), OXi4503 or other OXiGENE investigational compounds.

To learn more about the ongoing randomized, controlled Phase 2 study of ZYBRESTAT in combination with bevacizumab for patients with relapsed ovarian cancer, please visit http://www.clinicaltrials.gov/ct2/show/NCT01305213?term=combretastatin&rank=15 .

To learn more about the ongoing Phase 1 study of OXi4503 in patients with acute myelogenous leukemia (AML), please visit http://www.clinicaltrials.gov/ct2/show/NCT01085656?term=oxi4503&rank=3 .